Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimoxifene Gel vs Oral Tamoxifen in DCIS
NCT02993159Phase 2Completed
- Sponsor
- Northwestern University
- Start
- May 2017
- Primary completion
- Mar 2021
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of afimoxifene in ductal carcinoma in situ (DCIS) (2 arms), sponsored by Northwestern University. Primary endpoint: Change in Ki-67 Labeling Index at 10 weeks. Started May 2017; status: completed.
02
Drugs
afimoxifene
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT02993159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993159.